Abstract:Key Points A large fraction of point mutations that cause genetic diseases affect splicing efficiency and/or accuracy. Most of these mutations directly affect the canonical consensus sequences that define exon–intron boundaries, and are therefore correctly identified as 'splicing mutations'. Information that is present in the coding regions of genes also contributes to the correct identification of exon–intron boundaries. For example, exonic splicing enhancer (ESE) and silencer (ESS) elements are very prevalent and might be present in most, if not all, constitutive and alternative exons. ESEs are recognized by a class of splicing factors, the SR proteins, that promote splicing by recruiting spliceosomal components to the correct splice sites and/or by antagonizing the action of nearby silencers. Several classes of ESEs, which are recognized by different SR proteins, have been identified, and computational tools are being developed to predict the location, specificity and efficiency of putative ESEs. Because ESEs are embedded in protein-coding sequences, some nonsense, missense and translationally silent point mutations have actually been misclassified. Those mutations that inactivate an ESE can result in partial or complete exon skipping, and can therefore markedly affect the structure or amounts of the expressed protein product. An increasing proportion of point mutations are being reported to affect pre-mRNA splicing. Although reading-frame-dependent mechanisms have been proposed to account for nonsense-associated altered splicing (NAS), in most cases the disruption of ESEs or of RNA secondary structures that are required for proper splicing seems to be the mechanism that leads to exon skipping, regardless of the type of point mutation. Some coding single-nucleotide polymorphisms (cSNPs) can be expected likewise to disrupt elements that are involved in splicing and to exert a subtle effect on splice-site selection, thereby contributing to phenotypic variability, to the variable penetrance of mutations elsewhere in the gene and to cell-type-specific differences in gene expression. The effects of point mutations should be routinely analysed at the mRNA level before drawing conclusions about the importance of the affected amino acid, as their correct classification in terms of the actual mechanism of gene inactivation is essential for understanding structure–function relationships in the corresponding protein, for assessing the phenotypic risk in individuals with familial disease predispositions and for devising new therapies.

Widespread naturally variable human exons aid genetic interpretation

Alternative splicing at GYNNGY 5' splice sites: more noise, less regulation.

Genomic features defining exonic variants that modulate splicing

The human genome contains over a million autonomous exons

Prioritizing Single-Nucleotide Variations That Potentially Regulate Alternative Splicing.

Alternative splicing is coupled to gene expression in a subset of variably expressed genes

Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing

Species-specific Exon Loss in Human Transcriptomes.

A deep catalogue of protein-coding variation in 983,578 individuals

Sources of gene expression variation in a globally diverse human cohort

Genome-Wide Functional Annotation of Human Protein-Coding Splice Variants Using Multiple Instance Learning.

Protein-altering variants at copy number-variable regions influence diverse human phenotypes

Upstream open reading frames may contain hundreds of novel human exons

The impact of genetically controlled splicing on exon inclusion and protein structure

Exon Expression QTL (eeqtl) Analysis Highlights Distant Genomic Variations Associated with Splicing Regulation.

The human splicing code reveals new insights into the genetic determinants of disease

Listening to silence and understanding nonsense: exonic mutations that affect splicing

Global impact of unproductive splicing on human gene expression

Identification of synonymous pathogenic variants in monogenic disorders by integrating exome with transcriptome sequencing

Gene Variants in Noncoding Regions and Their Possible Consequences

Allelic Expression of Deleterious Protein-Coding Variants Across Human Tissues